Neurosom’s research partner, the Brain Electrophysiology Lab (BEL), has received $2.2 million in Phase II funding from the National Institutes of Aging to conduct an FDA-monitored clinical trial to determine if Neurosom’s Electric Sleep Therapy can improve deep sleep and memory consolidation in seniors with Mild Cognitive Impairment (MCI).
In the Phase I feasibility study, Neurosom scientists, together with colleagues at Wake Forest University (led by Dr. Ruth Benca) and the Portland Veterans Administration Research Foundation (led by Dr. Miranda Lim), demonstrated the ability to train seniors diagnosed with MCI to use the Neurosom Sleep WISP system in their homes to collect EEG (brain waves) and automatically deliver the electrical synchronization therapy to enhance deep sleep. This feasibility study was reviewed by the NIA program officer and found to be successful, thereby warranting the funding for the Phase II (pivotal) clinical trial.
Neurosom remains committed to testing its Electric Sleep Therapy in adults with insomnia, and plans to fund an FDA clinical trial with capital raised over the RedCrow platform.
For investors, the NIA decision to provide non-dilutive funding for the MCI clinical trial provides important validation of the Phase I feasibility study results and advances the incremental de-risking of the investment opportunity.
Learn more about Neurosom and its current capital raise here.
Disclaimer: The opinions expressed in this blog are those of the authors and do not represent the views and opinions of RedCrow or its affiliates. The blog does not imply a recommendation or endorsement by Redcrow. RedCrow does not verify or establish the truth of the information obtained in the blog. These materials may not be relied upon for making any investment decision. Nothing in the blog is to be construed as a securities offering.
